博瑞医药(688166.SH)：BGM0504片获得药物临床试验批准通知书

Core Viewpoint - 博瑞医药's subsidiary, 博瑞制药, has received approval from the National Medical Products Administration for clinical trials of BGM0504 tablets in overweight/obese adults, indicating progress in its drug development pipeline [1] Group 1: Product Development - BGM0504 is a dual agonist of GLP-1 and GIP receptors, designed to activate downstream pathways for controlling blood sugar, weight loss, and treating non-alcoholic steatohepatitis (NASH) [1] - The injectable form of BGM0504 is currently in Phase III clinical trials for type 2 diabetes and weight loss indications in China [1] - As of the announcement date, there are no approved oral formulations targeting the same receptors globally, highlighting a potential market opportunity for BGM0504 tablets [1]